Clinical Trials Logo

Filter by:
NCT ID: NCT06415500 Not yet recruiting - Gynecologic Cancer Clinical Trials

A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites

Start date: May 6, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of NK042 for treatment of malignant ascites.

NCT ID: NCT06414577 Not yet recruiting - Clinical trials for Nasopharyngeal Cancer

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Start date: May 15, 2024
Phase: Phase 2
Study type: Interventional

Nasopharyngeal cancer is a malignant tumor that arises from the cells of the nasopharyngeal epithelium, with its occurrence spread across different regions worldwide. Recent data from China in 2015 revealed approximately 6.0 million new cases of nasopharyngeal cancer, leading to approximately 34,000 deaths. When choosing a chemotherapy regimen for patients with metastatic nasopharyngeal cancer, the gemcitabine and cisplatin combination (GP) is typically recommended as the initial treatment. However, it is common for patients to experience disease progression after receiving first-line chemotherapy, highlighting the importance of a well-defined second-line treatment plan. Recent clinical studies have indicated that combining nituzumab with radiotherapy can enhance treatment efficacy with minimal side effects, providing promising results for advanced nasopharyngeal cancer patients. Additionally, the use of irinotecan liposome injection has proved beneficial in modifying the drug's pharmacokinetics, resulting in improved drug delivery to the tumor site while reducing toxicity in healthy tissues. This study aims to explore the effectiveness and safety of combining irinotecan liposome with nituzumab treatment for recurrent metastatic nasopharyngeal carcinoma that has not responded to initial immunotherapy. Participants selected for this clinical trial will receive a treatment regimen consisting of liposomal irinotecan administered intravenously at a dose of 70 mg/m2 on day 1, along with nituzumab given at a dose of 400 mg via intravenous injection on the same day. This treatment cycle will be repeated every two weeks for a maximum of eight cycles, or until disease progression, intolerable side effects, or other criteria necessitating discontinuation of treatment as determined by the investigator. By evaluating the efficacy and safety of this combined regimen, investigators aim to establish a novel therapeutic approach for managing advanced nasopharyngeal carcinoma in the context of current immunotherapy advancements.

NCT ID: NCT06414135 Not yet recruiting - Systemic Sclerosis Clinical Trials

Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

Start date: June 2024
Phase: Phase 1
Study type: Interventional

Relma-cel is a product containing CD19-CAR-transduced T cells. The purpose of this study is to evaluate the safety of Relma-cel at different dose levels in patients with early diffuse systemic sclerosis. Efficacy will be explored too. If enrolled, participants will undergo leukapheresis, lymphodepleting chemotherapy and administration of Relma-cel.

NCT ID: NCT06414018 Not yet recruiting - Effect of Drug Clinical Trials

Effect of Equivalent Dose Sufentanil and Afentanil in Bronchoscopic Treatment

EOEDSAAIBT
Start date: May 20, 2024
Phase: N/A
Study type: Interventional

The equivalent dose of sufentanil and afentanil combined with laryngeal mask was used for complex bronchoscopy to observe the intraoperative effect and the influence on the recovery of patients

NCT ID: NCT06413953 Not yet recruiting - Advanced Cancers Clinical Trials

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Start date: May 2024
Phase: Phase 1
Study type: Interventional

TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells. This clinical study aims to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).

NCT ID: NCT06413745 Not yet recruiting - Clinical trials for HER2 Expression / Amplification in Patients With Biliary Tract Cancer

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic treatment.

NCT ID: NCT06413654 Not yet recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorders

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Start date: June 20, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.

NCT ID: NCT06413615 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors

Start date: May 13, 2024
Phase: Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of FDA022-BB05 for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2 overexpressing/expressing solid tumors which are not eligible for curative therapy.

NCT ID: NCT06412471 Not yet recruiting - Clinical trials for First-line Advanced NSCLC Patients

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC.

NCT ID: NCT06412458 Not yet recruiting - Clinical trials for Recurrent Osteosarcoma

IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma

Start date: June 15, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study, a single-center, open, single-dose clinical study, was to evaluate the safety, tolerability, and pharmacokinetic profile of IM83 CAR-T cells in the treatment of patients with relapsed or refractory osteosarcoma